01 / DESIGN
What was studied?
The US trial randomized 281 adults with type 2 diabetes to retatrutide groups, placebo or an active dulaglutide comparator. The primary assessment was glycated hemoglobin change at 24 weeks.
02 / FINDINGS
What did the researchers report?
Most retatrutide groups improved glycated hemoglobin more than placebo, with weight changes also reported. Results varied by study group; gastrointestinal adverse events were frequent.
03 / LIMITS
How should it be interpreted?
The study was relatively small and short, and comparisons were with specific regimens. It does not settle long-term outcomes or support treating every result as a benefit shared by all triple-receptor compounds.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.